In response to the novel Coronavirus Disease (COVID-19) pandemic, SAMHSA is providing updates to Frequently Asked Questions (FAQs) regarding the provision of methadone and buprenorphine for the treatment of opioid use disorder for new and existing patients.
View Updated FAQs